GE HealthCare Technologies (GEHC) Investor Day 2024 summary
Event summary combining transcript, slides, and related documents.
Investor Day 2024 summary
8 Jul, 2026Strategic Priorities and Growth Framework
Targeting mid-single-digit organic revenue growth (4–6% CAGR) through 2028, driven by innovation, margin expansion, and recurring revenue.
Four strategic pillars: leadership products, business optimization, precision care, and new revenue models (SaaS, M&A).
R&D investment increased from 4% to 6% of sales, with over $2.2B invested since 2022 and a focus on high-impact product launches.
Recurring revenue now over 45% of total, with a long-term target of 60% through services, SaaS, and consumables; digital revenue expected to grow 50% to $1.8B by 2028.
Margin expansion plan targets high teens to 20%+ EBIT, supported by productivity, platforming, and innovation.
Innovation and Technology Strategy
Over 100 new products launched since the spin-off; 25+ imaging NPIs and 40 AVS NPIs planned for the midterm.
Leading in AI med tech with 80 FDA-cleared AI-enabled products, aiming for 200+ by 2028.
Major launches include photon counting CT (Deep Silicon), next-gen MR, Flyrcado (cardiac PET), Vizamyl (Alzheimer’s PET), and CareIntellect for Oncology.
Digital and SaaS backbone to enable new recurring revenue streams, with the first enterprise SaaS product launching in 2025.
Strategic M&A and partnerships to broaden capabilities in high-growth adjacencies and digital health.
Segment Highlights and Market Positioning
Imaging: $8.9B revenue, 9.2% EBIT margin, 4-5% market CAGR, 300,000+ installed base, focus on AI and molecular imaging.
AVS: $5.1B revenue, 800,000 installed base, 40 NPIs planned, integration of ultrasound and interventional labs for margin and growth.
PCS: $3.1B revenue, 4M installed base, 10 NPIs planned, targeting 400bps margin improvement via digital and supply chain.
PDx: $2.3B revenue, 26.8% margin, high single-digit growth, pipeline of 8 assets, leveraging unique integration with imaging.
Strategic partnerships and enterprise deals ($4B+ since spin) drive recurring revenue and customer stickiness.
Latest events from GE HealthCare Technologies
- Q2 2025 revenue and net income rose, guidance increased, and tariff mitigation improved outlook.GEHC
Q2 20258 Jul 2026 - Q3 net income rose 25% to $470M on 1% revenue growth, with U.S. and innovation offsetting China softness.GEHC
Q3 20248 Jul 2026 - Record orders, margin gains, and innovation drive growth outlook for 2025.GEHC
Q4 20248 Jul 2026 - Innovation, margin expansion, and new PET imaging launches drive strong growth outlook.GEHC
51st Nasdaq London Investor Conference30 Jun 2026 - Record backlog and robust pipeline set the stage for accelerated growth despite inflation headwinds.GEHC
Jefferies Global Healthcare Conference 20263 Jun 2026 - Inflation challenges cut guidance, but innovation and margin gains drive a strong long-term outlook.GEHC
Bank of America Global Healthcare Conference 202613 May 2026 - All proposals passed amid strong financials, innovation, and ongoing tariff and inflation mitigation.GEHC
AGM 20267 May 2026 - Revenue up 7.4% to $5.1B, but profit margins and outlook revised downward on inflation and tariffs.GEHC
Q1 202629 Apr 2026 - Strong 2025 results, record backlog, and margin expansion expected in 2026.GEHC
Q4 202513 Apr 2026